Matsuda Masaru's Form 4 filing
Arcutis Biotherapeutics, Inc. (ARQT) · filed Feb 4, 2026
- Accession no.
- 0001628280-26-005582
- Filed
- Feb 4, 2026
- Trade date
- Feb 2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.03M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Matsuda MasaruCIK 0001798679 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Common Stock | SSaleDisposed | −7,983 | $25.50 | −$203,566.5 | 142,658 | Direct | |
| Feb 2, 2026 | Common Stock | SSaleDisposed | −8,562 | $24.97 | −$213,793.14 | 134,096 | Direct | |
| Feb 2, 2026 | Common Stock | SSaleDisposed | −19,379 | $25.24 | −$489,125.96 | 114,717 | Direct | |
| Feb 2, 2026 | Common Stock | SSaleDisposed | −4,714 | $25.63 | −$120,819.82 | 110,003 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.